Cyclopropane compounds and pharmaceutical use thereof

Abstract

The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane compound of formula (1):wherein R1 is —(CH2)m—X—(CH2)n-A1 etc., wherein m and n are the same or different and each is 0 to 6, X is a single bond, etc. and A1 is a substituted C3-14 hydrocarbon ring group, etc.; R2 and R3 are the same or different and each is a hydrogen atom, —(CH2)p—X1—(CH2)q-A2, etc., wherein p and q are the same or different and each is 0 to 6, X1 is a single bond, etc. and A2 is an optionally substituted C3-14 hydrocarbon ring group, etc.; R4 is —CO2R9, etc., wherein R9 is a hydrogen atom, etc.; and R20 and R21 are the same or different and each is a hydrogen atom, —(CH2)m12—X12—(CH2)m12—R30, etc., wherein m12 and m12 are the same or different and each is 0 to 6, X12 is a single bond, etc. and R30 is a hydrogen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt thereof.

Description

[0001]This Application claims benefit of priority of U.S. provisional Application No. 60 / 529,116, filed Dec. 15, 2003, the contents of which are hereby incorporated by reference.[0002]The present invention relates to a novel cyclopropane compound. In further detail, the present invention relates to a cyclopropane compound or a pharmaceutically acceptable salt thereof having an aggrecanase inhibitory activity or matrix metalloproteinase (MMP) inhibitory activity, a pharmaceutical composition which comprises this compound and a pharmaceutical use thereof.[0003]Aggrecan is a main proteoglycan in cartilage, and decomposition of its core protein by protease is one of the early signs of a joint disorder associated with arthrodial cartilage destruction, such as rheumatoid arthritis and osteoarthritis. This process of decomposition leading to the cartilage destruction begins with the disappearance of aggrecan on the surface of cartilage, and progresses to the decomposition of collagen type ...

AI Technical Summary

Benefits of technology

[0004]At present, conservative treatments and surgical treatments are available for treating OA. The conservative therapy includes body weight control, exercise therapy, physical therapy, drug therapy (administration of anti-inflammatory drug), hyperthermia, and the like. It is a general practice to inject hyaluronic acid into the joint in the course of these treatments to smoothen movement of the joint.

[0009]The compound of the present invention possesses improved oral availability and shows strong aggrecanase inhibitory activity. While the compound is free of an MMP-1 inhibitory activity, it also has selective inhibitory activity of MMP-13, involved in joint destruction. Therefore, the compound is expected to suppress progress of joint diseases without causing side effects.

Problems solved by technology

However, artificial joints have a life of only about 15 to 20 years, after which the QOL (Quality of Life) of the patient deteriorates.

At present, no drug that suppresses enzyme involved in cartilage destruction is available for OA treatment.

In addition, the MMP inhibitors under development include a compound that causes systemic connective tissue toxicity due to nonselective collagenase inhibition.

It is clear, therefore, that the conventional products are not entirely satisfactory from the aspects of effective inhibition and occurrence of side effects.

Images